Cancer
Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer
March 8, 2019Medical Communications, Sales and Marketing Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma
Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with …
Dutch pharmacists to circumvent Novartis cancer drug market exclusivity
March 8, 2019Medical Communications Bruno Bairns, Cancer, Luathera, Novartis, aaa
Dutch pharmacists have vowed to circumvent rules enforcing Novartis’ market exclusivity for radioactive cancer drug Lutathera. Pharmacists at Erasmus, …
The cutting edge of cancer research
March 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, feature, oncology
While immunotherapies continue to be the darling of the industry, new, innovative and sometimes seemingly fantastical research is emerging that …
J&J sign deal with Scottish firm AdoRx to develop novel lung cancer treatments
March 1, 2019Medical Communications AdoRx, Cancer, Cancer Immunotherapy, J&J, JJ, immunology, oncology
Edinburgh-based drug discovery firm AdoRx therapeutics has signed a deal with US healthcare conglomerate Johnson & Johnson to develop novel …
Nearly half of childhood cancer cases go untreated and undiagnosed
March 1, 2019Medical Communications Cancer, childhood cancer, diagnosis, oncology, pediatric, world
Almost half of all children with cancer are going untreated and undiagnosed, according to research published in Lancet Oncology. While …
Read the March 2019 issue of Pharmafocus online now!
February 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease
Just one month to go until Brexit here in the UK, and it’s still all to play for. After months …
Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
February 26, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …
Living with melanoma after surgery
February 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma
Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …
Missouri Supreme Court ruling could help J&J in talc cases
February 25, 2019Sales and Marketing Cancer, J&J, JJ, asbestos, baby powder, lawsuits, legal, talc
The Missouri Supreme Court has ruled that the practice of combining two or more cases in order to allow courts …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
US Department of Justice investigate J&J over Baby Powder allegations
February 22, 2019Medical Communications Cancer, J&J, JJ, Johnson and Johnson, USA, asbestos, oncology, talc
The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that Johnson’s …
FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths
February 21, 2019Research and Development Cancer, FDA, Xencor, leukaemia, pharma
Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer
February 18, 2019Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer
Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
Smoking may limit immune system’s ability to fight cancer, study shows
February 18, 2019Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking
Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …
Latest content
Five Facts about cardiovascular disease
